Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
Earnings Data
Report Date
May 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
3.06Last Year’s EPS
3.02Same Quarter Last Year
Moderate Buy
Based on 27 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call conveyed balanced optimism: Biogen reported strong operating cash flow, solid EPS, a growing cohort of recently launched 'growth' products and meaningful pipeline and regulatory progress (priority review, breakthrough designation, new INDs and acquisition activity). These positives are tempered by near‑term revenue guidance calling for a mid‑single‑digit decline in 2026, ongoing competitive pressures on legacy MS products (generics and biosimilars), one‑time charges that weighed on GAAP results and reimbursement/inventory timing uncertainties that could dampen near‑term revenue trajectories. The company is investing for launches and pipeline progression while managing legacy declines.Company Guidance
Strong EPS, cash generation and balance sheet
Q4 non-GAAP diluted EPS $1.99; FY2025 non-GAAP diluted EPS $15.28 (came in above expectations). Free cash flow $2.1B for the year; cash and marketable securities $4.2B; net debt $2.0B; FY2025 total revenue $9.9B, up ~2% versus 2024.
Growth products driving momentum
Growth products generated $3.3B in FY2025 and >$800M in Q4 2025. Management highlighted strong year-over-year expansion for the growth portfolio (company commentary referenced substantial YoY increases for the growth cohort). Several recently launched products (since 2023) — Lekembi, Skyclaris, Xerxuve, and Calcadi — now generate >$1B combined.
Market leadership for anti-amyloid therapy (Lekembi)
Lekembi reported >60% share of the anti-amyloid therapy market; persistency after plaque‑removal reported at ~70%. Priority review secured for the subcutaneous induction (iClick) with a PDUFA date of May 24, 2026 — potential to reduce infusion burden and broaden access.
Notable product commercial wins
Xerxuve more than doubled sales in 2025. Skyclaris Q4 global revenue $133M, up ~30% YoY (U.S. Q4 $89M); Akembi end‑market sales booked by Eisai ~ $134M in Q4, noted as a step increase (+1054% versus Q3 2025 and Q4 2024 comparisons by management). VUMERITY FY2025 revenue $747M, +19% YoY.
Pipeline expansion and regulatory designations
Pipeline broadened materially during 2025: lidifolumab (litifolumab) received FDA Breakthrough Therapy designation for cutaneous lupus; multiple registrational readouts expected (e.g., litifolumab TOPAZ‑2 readout by end of 2026, BIB080 tau phase 2 mid‑year, SPINRAZA high‑dose PDUFA in April 2026). BTK degrader (BIG145) initiated phase 1 in healthy volunteers.
Strategic BD and acquisition activity
Acquisition of Alcion Therapeutics announced to improve delivery options for intrathecal therapies (e.g., potential convenience improvements for SPINRAZA). New collaborations completed in Q4 with Vanqua and Dara Therapeutics to broaden portfolio and R&D options.
BIIB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BIIB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 06, 2026 | $185.36 | $201.18 | +8.53% |
Oct 30, 2025 | $147.86 | $149.61 | +1.18% |
Jul 31, 2025 | $126.64 | $128.00 | +1.07% |
May 01, 2025 | $121.08 | $120.93 | -0.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biogen (BIIB) report earnings?
Biogen (BIIB) is schdueled to report earning on May 06, 2026, Before Open (Confirmed).
What is Biogen (BIIB) earnings time?
Biogen (BIIB) earnings time is at May 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BIIB EPS forecast?
BIIB EPS forecast for the fiscal quarter 2026 (Q1) is 3.06.
